<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995825</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00048923</org_study_id>
    <secondary_id>HHSF223201010144A</secondary_id>
    <nct_id>NCT01995825</nct_id>
  </id_info>
  <brief_title>Lamotrigine Bioequivalence</brief_title>
  <official_title>Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, brand name lamotrigine (LAMICTAL) and generic lamotrigine will be compared in&#xD;
      patients with epilepsy. Both the brand name and generic lamotrigine are approved by the Food&#xD;
      and Drug Administration (FDA) and are commonly used to treat epilepsy. Some physicians and&#xD;
      patients with epilepsy have believed that brand and generic lamotrigine have had clinically&#xD;
      significant differences in efficacy and tolerability. The brand name and generic tablets have&#xD;
      been shown to be the same when blood levels were measured in healthy volunteers without&#xD;
      epilepsy, but these drugs have not yet been compared in patients with epilepsy. This study&#xD;
      will do this comparison, by switching patients between brand and generic in a very structured&#xD;
      manner, and seeing if the drugs are the same, primarily in terms of blood levels. Other&#xD;
      comparisons will also be made secondarily, looking for any differences in adverse effects and&#xD;
      seizure control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As is commonly done in a bioequivalence study, the null hypothesis is that the generic (i.e.&#xD;
      test) is bioINequivalent to the brand name (i.e. reference). Hence, the alternative&#xD;
      hypothesis is that the generic is bioequivalent to the brand name.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0-12hr</time_frame>
    <description>pharmacokinetic exposure (ng*hr/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-12hr</time_frame>
    <description>highest concentration over the time duration 0-12hr (ng/ml)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Brand lamotrigine then Generic lamotrigine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crossover trial. Each arm will receive Brand lamotrigine tablet for two periods and Generic lamotrigine for two periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generic lamotrigine then Brand lamotrigine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crossover trial. Each arm will receive Generic lamotrigine tablet for two periods and Brand lamotrigine for two periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brand lamotrigine</intervention_name>
    <description>Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks</description>
    <arm_group_label>Brand lamotrigine then Generic lamotrigine</arm_group_label>
    <arm_group_label>Generic lamotrigine then Brand lamotrigine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic lamotrigine</intervention_name>
    <description>Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks</description>
    <arm_group_label>Brand lamotrigine then Generic lamotrigine</arm_group_label>
    <arm_group_label>Generic lamotrigine then Brand lamotrigine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able to provide informed consent.&#xD;
&#xD;
          -  Subject is male or female between 18 and 65 years of age inclusive.&#xD;
&#xD;
          -  Subject has a diagnosis of epilepsy with simple partial seizures and/or complex&#xD;
             partial seizures, with or without secondary generalization or primary generalized&#xD;
             seizures.&#xD;
&#xD;
          -  Subject has had a history of at least one seizure and/or AED related adverse event&#xD;
             with AED changes; or had at least one seizure and/or AED related adverse event over&#xD;
             the 12 months prior to Visit 1.&#xD;
&#xD;
          -  Subject has been maintained on a stable dose regimen of anti-epileptic drugs (AEDs),&#xD;
             including lamotrigine at 200mg, 400mg, or 600mg total daily dosage divided BID for at&#xD;
             least 28 days prior to Visit 1. Additionally, subject must be taking lamotrigine for 8&#xD;
             weeks prior to Visit 1.&#xD;
&#xD;
          -  Subject is willing to be switched between brand and generic lamotrigine.&#xD;
&#xD;
          -  Subject is an acceptable candidate for venipuncture.&#xD;
&#xD;
          -  Subject is willing to stop all OTC medications for 24 hours prior to and during 12&#xD;
             hour study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is currently participating or has participated within the last 2 months in any&#xD;
             trial of an investigational drug or experimental device.&#xD;
&#xD;
          -  Subject has a history of status epilepticus within the 12 month period prior to Visit&#xD;
             1.&#xD;
&#xD;
          -  Subject has any medical condition, which in the opinion of the investigator, could&#xD;
             jeopardize the subject's health or would compromise the subject's ability to&#xD;
             participate in the trial.&#xD;
&#xD;
          -  Subject has any psychiatric condition, which in the opinion of the investigator, could&#xD;
             jeopardize the subject's health or would compromise the subject's ability to&#xD;
             participate in this trial or confound the interpretation of the trial data.&#xD;
&#xD;
          -  Subject has known hypersensitivity to lamotrigine.&#xD;
&#xD;
          -  Subject has a medical condition that impacts drug absorption (e.g. gastric bypass&#xD;
             surgery), including routine use (i.e. daily or weekly) use of acid blockers, antacids,&#xD;
             anti-diarrhea, stimulants, appetite suppressants, or anti nausea medication or other&#xD;
             drugs that modulate GI function.&#xD;
&#xD;
          -  Subject has any history of alcohol or drug abuse within the previous two years.&#xD;
&#xD;
          -  Subject has acute or subacutely progressive CNS disease.&#xD;
&#xD;
          -  Subject has moderate or severe liver impairment as assessed by alanine&#xD;
             aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels â‰¥5&#xD;
             times the upper limit of normal (ULN).&#xD;
&#xD;
          -  Subject has moderate or severe renal impairment as assessed by creatinine clearance&#xD;
             lower than 50mL/min, using the Cockcroft-Gault formula.&#xD;
&#xD;
          -  Female subjects of childbearing potential will not be eligible to participate who are&#xD;
             unwilling or unable to use a medically acceptable method of contraception throughout&#xD;
             the entire study period and for one week after the study is completed. Medically&#xD;
             acceptable methods of contraception that may be used by the subject and/or her partner&#xD;
             are: condom with spermicide, diaphragm with spermicide, IUD without progesterone,&#xD;
             vaginal spermicidal suppository, surgical sterilization of their partner(s) or&#xD;
             abstinence.&#xD;
&#xD;
          -  Female subject is pregnant or nursing.&#xD;
&#xD;
          -  Female subject is using hormonal contraceptive precautions including&#xD;
             progesterone-coated IUD.&#xD;
&#xD;
          -  Subjects is using hormonal replacement therapy.&#xD;
&#xD;
          -  Subject is unwilling or unable to maintain their approximate daily smoking use during&#xD;
             the study.&#xD;
&#xD;
          -  Subject is using rifampin or other non-AED that strongly modulates lamotrigine levels.&#xD;
&#xD;
          -  In addition to lamotrigine and/or vagus nerve stimulation and/or intermittent&#xD;
             benzodiazepine use (e.g. lorazepam, diazepam, clonazepam), subject is taking more than&#xD;
             two concomitant AEDs.&#xD;
&#xD;
          -  Subject is not willing or able to be adherent to study protocol (e.g. dosing of&#xD;
             lamotrigine and any interacting comedication).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007 Mar;48(3):464-9.</citation>
    <PMID>17346246</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 26, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <results_first_submitted>November 3, 2015</results_first_submitted>
  <results_first_submitted_qc>November 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 1, 2020</results_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>James E Polli</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>lamotrigine</keyword>
  <keyword>epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Brand Lamotrigine Then Generic Lamotrigine</title>
          <description>Crossover trial. Each arm will receive Brand lamotrigine tablet for two periods and Generic lamotrigine for two periods.</description>
        </group>
        <group group_id="P2">
          <title>Generic Lamotrigine Then Brand Lamotrigine</title>
          <description>Crossover trial. Each arm will receive Generic lamotrigine tablet for two periods and Brand lamotrigine for two periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Brand Lamotrigine Then Generic Lamotrigine</title>
          <description>Crossover trial. Each arm will receive Brand lamotrigine tablet for two periods and Generic lamotrigine for two periods.</description>
        </group>
        <group group_id="B2">
          <title>Generic Lamotrigine Then Brand Lamotrigine</title>
          <description>Crossover trial. Each arm will receive Generic lamotrigine tablet for two periods and Brand lamotrigine for two periods.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>pharmacokinetic exposure (ng*hr/ml)</description>
        <time_frame>0-12hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brand Lamotrigine</title>
            <description>Brand lamotrigine tablet100mg tablets (1-3 either once or twice a day) for two weeks</description>
          </group>
          <group group_id="O2">
            <title>Generic Lamotrigine</title>
            <description>Generic lamotrigine tablet100mg tablets (1-3 either once or twice a day) for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>pharmacokinetic exposure (ng*hr/ml)</description>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101346" spread="6314"/>
                    <measurement group_id="O2" value="101393" spread="6421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>highest concentration over the time duration 0-12hr (ng/ml)</description>
        <time_frame>0-12hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brand Lamotrigine</title>
            <description>Brand lamotrigine tablet100mg tablets (1-3 either once or twice a day) for two weeks</description>
          </group>
          <group group_id="O2">
            <title>Generic Lamotrigine</title>
            <description>Generic lamotrigine tablet100mg tablets (1-3 either once or twice a day) for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>highest concentration over the time duration 0-12hr (ng/ml)</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10670" spread="657"/>
                    <measurement group_id="O2" value="10697" spread="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Brand Lamotrigine</title>
          <description>Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks</description>
        </group>
        <group group_id="E2">
          <title>Generic Lamotrigine</title>
          <description>Generic lamotrigine tablet100mg tablets (1-3 either once or twice a day) for two weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Polli</name_or_title>
      <organization>U of Maryland</organization>
      <phone>410-706-8292</phone>
      <email>jpolli@rx.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

